(NASDAQ: LYEL) Lyell Immunopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.43%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.71%.
Lyell Immunopharma's earnings in 2025 is -$334,522,000.On average, 4 Wall Street analysts forecast LYEL's earnings for 2025 to be -$219,509,641, with the lowest LYEL earnings forecast at -$240,109,436, and the highest LYEL earnings forecast at -$183,109,287. On average, 3 Wall Street analysts forecast LYEL's earnings for 2026 to be -$200,238,866, with the lowest LYEL earnings forecast at -$253,990,302, and the highest LYEL earnings forecast at -$121,088,400.
In 2027, LYEL is forecast to generate -$175,725,848 in earnings, with the lowest earnings forecast at -$259,897,053 and the highest earnings forecast at -$91,554,644.